Anterior chamber lenses in the management of subluxated lenses

Article

Anterior chamber lenses in the management of subluxated lenses

Ophthalmology needs a large-scale, probably multicentre prospective trial to fully understand and codify the management of subluxated lenses, according to Dr Gunther Grabner, addressing delegates meeting in Barcelona.

“We need the data to create a decision tree to help surgeons find the best option for these cases among those available,” he said. Doctors need better data to help them decide between surgical options.

Dr. Grabner said that subluxated lenses are an uncommon condition. A study of cases at his clinic showed that it was less than 0.94% per year, which is comparable to similar clinics. “It is 1 out of every 226 cataract surgery cases, so we can say it's a fairly uncommon event.”

He said the surgical options in these cases included anterior chamber lenses (ACL) as the angle supported and iris claw, and posterior chamber lens (PCL) options included the sclera fixated, iris sutured or posteriorly enclavated iris claw lens.

Angle supported lenses were reported to have performed very well and were indicated in the presence of bleeding disorders, extensive sclerocorneal scarrin, an intact anterior vitreous face and when surgery had to be quick, as with older patients.

However, they should not be used where there were corneal endothelial problems or shallow chamber, abnormal angle, or where there was glaucoma and iris-defects, such as aniridia. “I don't think they should be used in patients with a life expectancy of more than 10 years,” he said.

Outlining the advantage of ACLs over PCLs , he said ACLs offer short surgical time, less bleeding, easy insertion and removal with minimal or no vitrectomy required. “And there are no problems of haptic placement, lens tilt and dislocation,” he noted.

Other advantages included no suture problems, minimal uveal contact and long term proven biocompatibility. PCLs, on the other, held the advantage in eyes with angle problems or endothelial damage, and PCLs are not dependent on the condition of the iris.

Dr. Grabner wound up his talk by demonstrating his surgery technique for posteriorally enclavated iris claw lens, which he said he liked a lot. However, he concluded by saying: “I think we have very few comparative, long-term studies comparing anterior chamber lenses and the other options. I think we have a need for a long term study.”

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.